Last checked at 26 Jan 2023 10:10
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Exercise of Options and Total Voting Rights
Brighton, United Kingdom - 26 January 2023 - Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it has issued and allotted 150,000 new ordinary shares of 1 pence each in the capital of the Company (the "New Ordinary Shares") following an exercise of share options by a former director.
Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 01 February 2023 ("Admission").
Following Admission, the Company will have a total of 73,457,105 Ordinary Shares in issue. Shareholders may use this figure of 73,457,105 Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Destiny Pharma plc Neil Clark, CEOShaun Claydon, CFO+44 (0)1273 704 440 pressoffice@destinypharma.com
Optimum Strategic Communications Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper +44 (0) 203 922 0891DestinyPharma@optimumcomms.com
finnCap Ltd (Nominated Advisor and Joint Broker) Geoff Nash / George Dollemore, Corporate FinanceAlice Lane / Nigel Birks / Harriet Ward, ECM+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
MC Services AG Anne Hennecke / Andreas Burckhardt+49-211-529252-12
Stern IR - US
Janhavi Mohite
+1-212-362-1200
Janhavi.Mohite@sternir.com